Search This Blog

Wednesday, November 5, 2014

Lilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy (NYSE:LLY)

CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy



Lilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.